Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Details are as follows:

JMP Securities 2024 Life Sciences Conference Date: Tuesday, May 14 Presentation Time: 11:00 a.m. ET Location: New York Hilton Midtown, 1335 Sixth Avenue, New York, NY

TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA Date: Wednesday, May 29 Presentation Time: 1:00 p.m. ET Location: Virtual

To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARa agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507063235/en/

SOURCE: Syros Pharmaceuticals

<img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&sty=20240507063235r1&sid=cmtx6&distro=nx&lang=en" style="width:0;height:0" />

Syros Contact 
Karen Hunady
Director of Corporate Communications & Investor Relations
1-857-327-7321
khunady@syros.com


Investor Contact 
Amanda Isacoff
Stern Investor Relations, Inc.
212-362-1200
amanda.isacoff@sternir.com

COMTEX_452008964/1006/2024-05-07T09:00:02